SynCore Biotechnology Co Ltd (4192) — Cash Flow-to-Debt Ratio
SynCore Biotechnology Co Ltd (4192) has a Cash Flow-to-Debt Ratio of -0.48x as of September 2025, meaning its operating cash flow of NT$-7.18 Million could theoretically repay 0% of its total liabilities (NT$14.88 Million) in one year. Explore how much of SynCore Biotechnology Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SynCore Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for SynCore Biotechnology Co Ltd across 10 annual periods. Also explore 4192 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for SynCore Biotechnology Co Ltd (2015–2024)
Year-by-year debt coverage analysis for SynCore Biotechnology Co Ltd. For market capitalisation and broader financial context, see SynCore Biotechnology Co Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.13x | NT$-49.24 Million | NT$23.11 Million | ▲ +45.1% |
| 2023 | -3.88x | NT$-82.37 Million | NT$21.23 Million | ▼ -247.4% |
| 2022 | -1.12x | NT$-209.61 Million | NT$187.64 Million | ▼ -85.4% |
| 2021 | -0.60x | NT$-229.86 Million | NT$381.52 Million | ▲ +32.8% |
| 2020 | -0.90x | NT$-316.63 Million | NT$353.41 Million | ▲ +67.5% |
| 2019 | -2.76x | NT$-418.57 Million | NT$151.84 Million | ▲ +0.7% |
| 2018 | -2.78x | NT$-272.26 Million | NT$98.11 Million | ▼ -72.1% |
| 2017 | -1.61x | NT$-201.96 Million | NT$125.28 Million | ▼ -22.7% |
| 2016 | -1.31x | NT$-195.09 Million | NT$148.46 Million | ▼ -55.4% |
| 2015 | -0.85x | NT$-156.03 Million | NT$184.46 Million | — |